Today: 1 March 2026
Subscribe
Browse Category

NYSE:PFE 19 December 2025 - 30 December 2025

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer shares slipped 0.1% to $25.06 in thin holiday trading Monday, with the stock moving between $24.99 and $25.19. Investors focused on Pfizer’s 2026 outlook and pipeline moves, including a $150 million licensing deal with China’s YaoPharma for an experimental obesity drug. Broader U.S. markets declined as tech stocks retreated. Pfizer expects revenue growth to resume in 2029.
29 December 2025
···
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer shares closed Friday at $25.09, trading in a narrow range on light volume ahead of the New Year’s holiday. No new company press releases have appeared since Dec. 18. The stock remains below its 52-week high of $27.69, with dividend yield drawing investor focus as Wall Street weighs declining COVID revenues against future growth in oncology and obesity drugs.
27 December 2025
···
Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer shares closed at $25.03 on Dec. 24, ahead of Christmas, after the company issued 2026 guidance below Wall Street forecasts. The drugmaker projected 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and loss of exclusivity. Pfizer declared a $0.43 per share Q1 2026 dividend, its 349th consecutive payout.
25 December 2025
···
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer shares traded near $25 on Dec. 24, 2025, valuing the company at about $142 billion amid thin holiday trading. The company’s 2026 guidance, released Dec. 16, projects revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with growth not expected to rebound until later in the decade. Investors remain focused on drug pricing risks, pipeline progress, and looming patent expirations.
24 December 2025
···
Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

Pfizer shares traded near $24.93 in thin holiday trading Dec. 24 after the company reported a patient death in a long-term study of its hemophilia drug Hympavzi. The company said it does not expect the event to alter the drug’s safety profile. U.S. policy moves to lower drug costs also weighed on sentiment. Pfizer reaffirmed 2025 earnings guidance and issued conservative 2026 forecasts.
24 December 2025
·
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer shares closed down 1.31% at $24.88 on December 23 after news that a patient died in a long-term trial of its hemophilia drug Hympavzi. The patient suffered a stroke and brain hemorrhage following minor surgery, according to the European Haemophilia Consortium. Trading volume was lighter than average ahead of the holiday. Pfizer said it is working with investigators and regulators to review the case.
24 December 2025
··
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer shares traded near $25.15 on Dec. 23 after a fatal thrombotic stroke was reported in a patient on its hemophilia therapy Hympavzi, prompting scrutiny from advocacy groups. The company also issued 2026 guidance projecting revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, below analyst expectations.
23 December 2025
···
Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer Stock Outlook for 2026: Oncology Momentum, Obesity Deals, and the Patent Cliff Investors Can’t Ignore

Pfizer on Dec. 22 announced a new metastatic prostate cancer research program with Flagship Pioneering and Repertoire Immune Medicines, the eighth under their alliance. The move follows Pfizer’s Dec. 16 guidance projecting flat-to-down 2026 revenue, ongoing COVID product declines, and increased R&D spending. Management warned of “bumpy” years ahead as exclusivity losses weigh on sales.
22 December 2025
····
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer shares closed at $25.19 on Dec. 19, down 4.7% from earlier in the week after the company issued 2026 guidance projecting flat or lower reported results. The company expects 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and loss of exclusivity. Market cap stands near $114 billion.
21 December 2025
··
Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer Stock (PFE) in Focus: 2026 Guidance, Drug-Price Deal Pressures, and Pipeline Catalysts Investors Are Watching

Pfizer forecast 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. The company expects a $1.5 billion drop in COVID product sales and another $1.5 billion hit from patent expirations. Pfizer signed a Medicaid pricing deal with the Trump administration, warning of margin compression. Shares closed at $25.25 on Dec. 19.
21 December 2025
··
Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer Stock (NYSE: PFE) on Dec. 20, 2025: 2026 Forecast, Dividend Outlook, and the Catalysts Wall Street Is Watching

Pfizer shares traded near $25.19 as of Dec. 20, 2025, following the company’s 2026 guidance projecting $59.5–$62.5 billion in revenue and adjusted EPS of $2.80–$3.00. The stock saw heavy volume after management cited lower COVID sales, patent expiries, and deal dilution as headwinds. U.S. drug-pricing deals and new Medicare pilot programs added pressure.
21 December 2025
····
Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, TrumpRx Drug-Pricing Deals, Dividend, and Analyst Forecasts (Dec. 20, 2025)

Pfizer shares closed at $25.19 after a volatile week marked by a sharp selloff following new 2026 guidance. The company forecasted 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with COVID-19 product sales expected to drop further. Management signaled no return to revenue growth until 2029, citing patent expirations and pricing pressures.
20 December 2025
···
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Price Targets, Dividend Outlook and Key Catalysts on Dec. 19, 2025

Pfizer shares closed at $25.37 on Dec. 19, 2025, up 1.3% with volume near 43.5 million. The company forecast 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and patent expirations as key drags. Investors tracked a positive bladder cancer trial and new U.S. drug-pricing rules affecting Pfizer’s portfolio.
19 December 2025
··
Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer Stock (PFE) Forecast and News: 2026 Guidance, Drug-Pricing Deals, and Pipeline Catalysts to Watch on Dec. 19, 2025

Pfizer shares traded near $25.04 midday Friday after a volatile week, holding steady despite new policy headlines and a guidance reset. The company issued 2026 revenue guidance of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, both below Wall Street estimates. Pfizer also reported positive Phase 3 results for PADCEV + Keytruda in bladder cancer.
19 December 2025
···
1 2 3 4 5 6 … 9
Go toTop